Viking Therapeutics (VKTX)
Health Care · Obesity and metabolic disorder therapeutics
Viking is developing VK2735, a novel dual GLP-1/GIP receptor agonist in Phase 3 trials for obesity and metabolic disorders, targeting a high-growth market currently dominated by single-agent GLP-1 therapies.
What Viking Therapeutics does
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders. The company's lead candidate, VK2735, is a dual agonist of GLP-1 and GIP receptors being developed in both oral and subcutaneous formulations for obesity and related metabolic disorders. VK2735 has completed Phase 2 trials demonstrating significant weight loss efficacy, with Phase 3 trials (VANQUISH-1 and VANQUISH-2) initiated in 2025.
Themes: ["GLP-1 / obesity and weight management","Metabolic disorders","Endocrine disorders","Dual GLP-1/GIP agonists"]
Fundamentals
- Price$39.96 as of 2026-07-09 close
- Market cap$4.7B as of 2026-07-09
- 1-year return+32.4% as of 2026-07-09 close
- ROE-71.3% as of 2026-07-09
- Debt / equity0.00 as of 2026-07-09
- Beta0.64 as of 2026-07-09
Key risks (from latest filing)
["VK2735 is still in clinical development with Phase 3 trials ongoing; regulatory approval is not guaranteed and clinical trial results may not translate to commercial success.","The obesity therapeutics market is highly competitive with established players (Novo Nordisk, Eli Lilly) having marketed GLP-1 agonists; Viking's novel dual agonist approach faces competition from both existing and pipeline products.","As a clinical-stage company with no approved products, Viking is dependent on raising additional capital to fund ongoing clinical trials and operations."]
Competitors & peers
- Novo Nordisk (NVO)
- Eli Lilly (LLY)
- Roche Pharmaceuticals
- Amgen (AMGN)
- Viking's competitors in dual/combination GLP-1 approaches
Fundamentals: Finnhub, as of 2026-07-09. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.